Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “treatment”

2,520 pharma patents match "treatment" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,520
Index total 30,257
Page 25 / 105

Quick answer

This filtered view shows 2,520 pharmaceutical patents matching "treatment" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,520 results for “treatment” · 30,257 patents in full index Clear search

  1. US 11434300

    Methods and antibody compositions for tumor treatment

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted

  2. US 11426448

    Methods for treatment of erectile dysfunction with sonic hedgehog compounds

    The Board of Regents of the University of Texas System · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  3. US 11426415

    Treatment for Wolfram syndrome and other endoplasmic reticulum stress disorders

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  4. US 11426379

    Combination of local and systemic therapies for enhanced treatment of dermatologic conditions

    Provectus Pharmatech, Inc. · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  5. US 11427838

    Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders

    Vertex Pharmaceuticals Incorporated · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  6. US 11426373

    Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

    Jazz Pharmaceuticals Ireland Limited · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  7. US 11427816

    Cancer treatment through RLIP76 partial depletion

    The Board of Regents of the University of Texas System · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  8. US 11421010

    T cells expressing membrane-anchored IL-12 for the treatment of cancer

    The Board of Regents of the University of Texas System · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted

  9. US 11419835

    Method of treatment and prevention of bacterial vaginosis

    Evofem, Inc. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted

  10. US 11420936

    Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases

    NIKANG THERAPEUTICS, INC. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted

  11. US 11413296

    Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

    The Regents of the University of California · Granted Aug 16, 2022 · Expires Aug 11, 2042

    granted

  12. US 11413303

    Methods for treatment of arthritis

    GALECTIN THERAPEUTICS, INC. · Granted Aug 16, 2022 · Expires Aug 11, 2042

    granted

  13. US 11413255

    Multifunctional cytoprotectant for treatment of pathogenic processes mediated by oxidative stress and toxic electrophiles

    Montefiore Medical Center · Granted Aug 16, 2022 · Expires Aug 11, 2042

    granted

  14. US 11413337

    Peptide conjugated particles for the treatment of inflammation

    Northwestern University · Granted Aug 16, 2022 · Expires Aug 11, 2042

    granted

  15. US 11413240

    Methylene blue solution for the treatment of oral lesions

    The Board of Regents of the University of Texas System · Granted Aug 16, 2022 · Expires Aug 11, 2042

    granted

  16. US 11414439

    Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Vertex Pharmaceuticals Incorporated · Granted Aug 16, 2022 · Expires Aug 11, 2042

    granted

  17. US 11407822

    Treatment of fibrodysplasia ossificans progressiva

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted

  18. US 11407723

    Selective histone deacetylase inhibitors for the treatment of human disease

    Shuttle Pharmaceuticals, Inc. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted

  19. US 11406643

    Targeting kinases for the treatment of cancer metastasis

    The Board of Regents of the University of Texas System · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted

  20. US 11407997

    Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders

    CRISPR THERAPEUTICS AG · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted

  21. US 11400143

    Compositions and methods for treatment of homocystinuria

    The Regents of the University of Colorado · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  22. US 11400096

    Small molecules for the treatment of autoimmune disorders

    The Board of Regents of the University of Texas System · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  23. US 11401256

    Dihydroquinolinones for medical treatment

    C4 THERAPEUTICS, INC. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  24. US 11400072

    Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy

    Coherus BioSciences, Inc. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.